MX2021009868A - Nuevo derivado de pirido[3,4-d]pirimidin-8-ona que tiene actividad inhibidora de proteína cinasa y composición farmaceutica para prevenir, aliviar o tratar el cáncer, que comprende el mismo. - Google Patents
Nuevo derivado de pirido[3,4-d]pirimidin-8-ona que tiene actividad inhibidora de proteína cinasa y composición farmaceutica para prevenir, aliviar o tratar el cáncer, que comprende el mismo.Info
- Publication number
- MX2021009868A MX2021009868A MX2021009868A MX2021009868A MX2021009868A MX 2021009868 A MX2021009868 A MX 2021009868A MX 2021009868 A MX2021009868 A MX 2021009868A MX 2021009868 A MX2021009868 A MX 2021009868A MX 2021009868 A MX2021009868 A MX 2021009868A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrimidin
- pharmaceutical composition
- derivative
- alleviate
- prevent
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 8
- 201000011510 cancer Diseases 0.000 title abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- HALYIFFLOBGDNN-UHFFFAOYSA-N 7h-pyrido[3,4-d]pyrimidin-8-one Chemical class N1=CN=C2C(=O)NC=CC2=C1 HALYIFFLOBGDNN-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 206010027476 Metastases Diseases 0.000 abstract 2
- 230000001028 anti-proliverative effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000009401 metastasis Effects 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- -1 pyrido[3,4-d]pyrimidin-8-one derivative compound Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente exposición se refiere a un compuesto derivado de pirido[3,4-d]pirimidin-8-ona que presenta excelentes efectos antiproliferativos contra las células cancerosas, una sal farmacéuticamente aceptable del mismo, un hidrato del mismo o un estereoisómero del mismo, un método de producción del mismo, una composición farmacéutica para prevenir, aliviar o tratar la metástasis del cáncer y la enfermedad. proliferativa que lo contiene como ingrediente activo, y una composición anticancerígena contra las células cancerosas. El compuesto exhibe una excelente actividad inhibidora de las células cancerosas y efectos antiproliferativos y, por lo tanto, es eficaz para inhibir las células cancerosas, prevenir la metástasis del cáncer y las enfermedades proliferativas o tratar el cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190018704A KR102747104B1 (ko) | 2019-02-18 | 2019-02-18 | 단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물 |
| PCT/KR2020/002213 WO2020171499A1 (ko) | 2019-02-18 | 2020-02-17 | 단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009868A true MX2021009868A (es) | 2022-01-04 |
Family
ID=72143523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009868A MX2021009868A (es) | 2019-02-18 | 2020-02-17 | Nuevo derivado de pirido[3,4-d]pirimidin-8-ona que tiene actividad inhibidora de proteína cinasa y composición farmaceutica para prevenir, aliviar o tratar el cáncer, que comprende el mismo. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220135559A1 (es) |
| EP (1) | EP3929195A4 (es) |
| JP (1) | JP7262599B2 (es) |
| KR (1) | KR102747104B1 (es) |
| CN (1) | CN113646307B (es) |
| AU (1) | AU2020225048B2 (es) |
| BR (1) | BR112021016132A2 (es) |
| CA (1) | CA3130568A1 (es) |
| MX (1) | MX2021009868A (es) |
| WO (1) | WO2020171499A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| KR102871791B1 (ko) | 2018-09-10 | 2025-10-15 | 미라티 테라퓨틱스, 인크. | 병용 요법 |
| SI3849537T1 (sl) | 2018-09-10 | 2025-03-31 | Mirati Therapeutics, Inc. | Kombinirane terapije |
| CA3111980A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2020055760A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| MX2021002804A (es) | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| JP7592601B2 (ja) | 2019-01-10 | 2024-12-02 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| AU2020337938B2 (en) | 2019-08-29 | 2025-09-25 | Array Biopharma Inc. | KRas G12D inhibitors |
| JP2022548791A (ja) | 2019-09-24 | 2022-11-21 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| AU2020405170A1 (en) | 2019-12-20 | 2022-06-30 | Mirati Therapeutics, Inc. | SOS1 inhibitors |
| KR102396930B1 (ko) * | 2020-01-15 | 2022-05-12 | 한국과학기술연구원 | 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 |
| AU2021340716A1 (en) | 2020-09-11 | 2023-03-30 | Mirati Therapeutics, Inc. | Crystalline forms of a KRas G12C inhibitor |
| CA3198943A1 (en) | 2020-11-18 | 2022-05-27 | Daniel L. Flynn | Gcn2 and perk kinase inhibitors and methods of use thereof |
| US12398154B2 (en) | 2020-12-15 | 2025-08-26 | Mirati Therapeutics, Inc. | Azaquinazoline pan-KRas inhibitors |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| WO2023239165A1 (ko) * | 2022-06-08 | 2023-12-14 | 한국화학연구원 | 페닐설폰아마이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06001098A (es) * | 2003-07-29 | 2006-04-24 | Irm Llc | Compuestos y composiciones utiles como inhibidores de proteina cinasa. |
| WO2005011587A2 (en) * | 2003-07-30 | 2005-02-10 | New Century Pharmaceuticls | Chalaropsis lysozyme protein and its method of use in anti-bacterial applications |
| EP1981886B1 (en) * | 2006-01-31 | 2009-08-12 | F.Hoffmann-La Roche Ag | 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors |
| EP2112150B1 (en) * | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
| WO2010002779A2 (en) * | 2008-07-03 | 2010-01-07 | Merck Serono S.A. | Naphthyridininones as aurora kinase inhibitors |
| US9765039B2 (en) * | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| US9073878B2 (en) * | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| CN103012428A (zh) * | 2013-01-08 | 2013-04-03 | 中国药科大学 | 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途 |
| GB201306610D0 (en) * | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| ITBO20130393A1 (it) | 2013-07-23 | 2015-01-24 | Ima Ind Srl | Dispositivo di saldatura ad ultrasuoni |
| KR101897631B1 (ko) * | 2016-08-10 | 2018-09-12 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 3,4-다이하이드로피리미도[4,5-d]피리미딘-2(1H)-온 골격의 유레아 화합물 |
| EP3524603B1 (en) * | 2016-12-19 | 2022-06-08 | Abbisko Therapeutics Co., Ltd. | Fgfr4 inhibitor, preparation method therefor and pharmaceutical use thereof |
| WO2018130184A1 (zh) * | 2017-01-13 | 2018-07-19 | 江苏恒瑞医药股份有限公司 | 1,2,4-三嗪-3-胺类衍生物、其制备方法及其在医药上的应用 |
-
2019
- 2019-02-18 KR KR1020190018704A patent/KR102747104B1/ko active Active
-
2020
- 2020-02-17 MX MX2021009868A patent/MX2021009868A/es unknown
- 2020-02-17 CN CN202080026915.3A patent/CN113646307B/zh active Active
- 2020-02-17 EP EP20759694.1A patent/EP3929195A4/en active Pending
- 2020-02-17 US US17/431,591 patent/US20220135559A1/en not_active Abandoned
- 2020-02-17 CA CA3130568A patent/CA3130568A1/en active Pending
- 2020-02-17 AU AU2020225048A patent/AU2020225048B2/en active Active
- 2020-02-17 BR BR112021016132-5A patent/BR112021016132A2/pt unknown
- 2020-02-17 JP JP2021548608A patent/JP7262599B2/ja active Active
- 2020-02-17 WO PCT/KR2020/002213 patent/WO2020171499A1/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN113646307A (zh) | 2021-11-12 |
| AU2020225048A1 (en) | 2021-09-16 |
| EP3929195A4 (en) | 2022-11-30 |
| JP7262599B2 (ja) | 2023-04-21 |
| NZ779245A (en) | 2024-08-30 |
| CA3130568A1 (en) | 2020-08-27 |
| EP3929195A1 (en) | 2021-12-29 |
| WO2020171499A1 (ko) | 2020-08-27 |
| US20220135559A1 (en) | 2022-05-05 |
| AU2020225048B2 (en) | 2023-02-23 |
| CN113646307B (zh) | 2024-07-30 |
| KR20200100429A (ko) | 2020-08-26 |
| BR112021016132A2 (pt) | 2021-10-13 |
| KR102747104B1 (ko) | 2024-12-27 |
| JP2022521901A (ja) | 2022-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009868A (es) | Nuevo derivado de pirido[3,4-d]pirimidin-8-ona que tiene actividad inhibidora de proteína cinasa y composición farmaceutica para prevenir, aliviar o tratar el cáncer, que comprende el mismo. | |
| MX2023002688A (es) | Compuestos farmaceuticos de arilo, heteroarilo, y heterociclicos para el tratamiento de trastornos medicos. | |
| MX2020003593A (es) | Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos. | |
| RU2018135973A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
| MX2021011563A (es) | Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. | |
| MX390503B (es) | Compuesto de pirimidina fusionada o sal del mismo. | |
| WO2016118951A3 (en) | Heterocyclic itk inhibitors for treating inflammation and cancer | |
| BR112019006047A2 (pt) | compostos, um ou dois ou mais compostos, sal farmaceuticamente aceitável, sal metanossulfonato, inibidor de quinase ret, medicamento, usos do composto e de um composto, métodos para tratar ou prevenir câncer e para tratar ou prevenir câncer em um indivíduo, e, composição farmacêutica | |
| MX2019003095A (es) | Combinaciones terapeuticas que comprenden un inhibidor de raf y un inhibidor de erk. | |
| WO2013019058A3 (en) | Pharmaceutical composition for inhibiting cancer recurrence or metastasis | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| WO2015095819A3 (en) | Cancer treatment using combinations of erk and raf inhibitors | |
| PH12016502103A1 (en) | Novel disubstituted 1,2, 4-triazine compound | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| MX387969B (es) | Composiciones y compuestos terapéuticos, y métodos para su uso. | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| WO2016004404A3 (en) | Gls1 inhibitors for treating disease | |
| MX2021008667A (es) | Derivado de pirrolopirimidina y composición farmacéutica para prevenir o tratar enfermedades relacionadas con la proteína quinasa que comprende el mismo como principio activo. | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| CR20190201A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| WO2016004413A3 (en) | Gls1 inhibitors for treating disease | |
| MX384072B (es) | Compuesto derivado de pirrolo-piridina, metodo para preparar el mismo y composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o el tratamiento de enfermedades relacionadas con la proteina cinasa. | |
| EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида | |
| ZA201901367B (en) | Inhibition of olig2 activity |